Multistate assessment of SARS-CoV-2 seroprevalence in blood donors
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-ncov/index.html

Multistate assessment of SARS-CoV-2 seroprevalence in blood donors

Filetype[PDF-176.19 KB]


English
Details Supporting Files You May Also Like

Details:

  • Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
  • Description:
    Updated Nov. 13, 2020

    CDC is conducting a nationwide COVID-19 seroprevalence survey of blood donors to:

    • Understand the percentage of people in the United States who have antibodies against SARS-CoV-2, the virus that causes COVID-19.

    • Track how this percentage changes over time.

    This study is the largest nationwide COVID-19 seroprevalence survey to date. CDC is collaborating on this project with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States. CDC is providing technical assistance and financial support to VRI and collaborating institutions.

    Conducted under REDS-IV-P (Recipient Epidemiology and Donor Evaluation Study IV Pediatric) programexternal icon, this seroprevalence survey expands an ongoing project called the RESPONSE studyexternal icon (REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic) funded by the NIH. From March to August 2020, the RESPONSE study collected existing blood donation samples from six U.S. regions (about 1000 samples per month) for testing for SARS-CoV-2 antibodies.

    The expanded seroprevalence survey includes more than 60 regions, representing all 50 states and Puerto Rico. Since July 2020, anonymous blood donation samples (about 2,000 per month) from each region are being collected and tested. The survey will continue until January 2022. A larger number of samples are being collected from blood centers in regions that encompass multiple states or are racially and ethnically diverse. Overall, about 1.5 million samples will be tested. For each region, the seroprevalence will be estimated for the region overall and by age group, sex, and race/ethnicity.

  • Content Notes:
    About this survey -- Information on blood donation samples tested -- Safety of US blood supply -- Interpreting Serology Results from This Survey.
  • Subjects:
  • Document Type:
    Webpage
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov